Monalizumab

Monalizumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.

Monalizumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Monalizumab Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
ShangHai Biochempartner Co.,Ltd	17754423994 17754423994	2853530910@QQ.com	China	8011	62
Beijing Solarbio Science & Tecnology Co., Ltd.	010-50973130 4009686088	3193328036@qq.com	China	29796	68
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10055	58
AntibodySystem	027-65279366 18162686757	biolab-reagents@atagenix.com	China	9819	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 13720134139	orders@jknbiochem.com	China	5224	58
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd	021-59167510 18117107507	vip@med-life.cn	China	5019	58
Shanghai Youna Biopharmaceutical Co., Ltd	18164002430	511710754@qq.com	China	223	58
Shanghai jerryxing Biomedical Technology Co., Ltd	17721492509	643638326@qq.com	China	5347	58
Changsha Fuzhen Biotechnology Co.，LTD	0731-18670069958 18670069958	184792226@qq.com	China	3060	58

---

• Monalizumab
• Research Grade Monalizumab(DHD71901)
• 1228763-95-8